BiotechTube

mFOLFOX regimen + Mitazalimab

Phase 2/3Recruiting
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Biliary Tract Cancer (BTC)

Conditions

Biliary Tract Cancer (BTC)

Trial Timeline

Jul 1, 2026 → Oct 1, 2031

NCT ID
NCT07437287

About mFOLFOX regimen + Mitazalimab

mFOLFOX regimen + Mitazalimab is a phase 2/3 stage product being developed by Alligator Bioscience AB for Biliary Tract Cancer (BTC). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07437287. Target conditions include Biliary Tract Cancer (BTC).

What happened to similar drugs?

2 of 20 similar drugs in Biliary Tract Cancer (BTC) were approved

Approved (2) Terminated (0) Active (18)
🔄Rilvegostomig + Durvalumab + Gemcitabine/CisplatinAstraZenecaPhase 3
🔄durvalumabAstraZenecaPhase 3
🔄Rilvegostomig + Placebo + Capecitabine + Gemcitabine/Cisplatin + S-1 [Tegafur/Oteracil/gimeracil]AstraZenecaPhase 3
🔄Gemcitabine + Cisplatin + Durvalumab + Trastuzumab deruxtecan + RilvegostomigAstraZenecaPhase 3
🔄Durvalumab + Gemcitabine monotherapy + Gemcitabine + cisplatin + Gemcitabine + oxaliplatin + Gemcitabine + carboplatin + Gemcitabine + cisplatin + S-1 + Gemcitabine + S-1 + Gemcitabine + cisplatin + albumin-bound paclitaxelAstraZenecaPhase 3
🔄Durvalumab + PlaceboAstraZenecaPhase 3
🔄Pembrolizumab + Gemcitabine + Cisplatin + PlaceboMerckPhase 3

Hype Score Breakdown

Clinical
15
Activity
15
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07437287Phase 2/3Recruiting

Competing Products

20 competing products in Biliary Tract Cancer (BTC)

See all competitors
ProductCompanyStageHype Score
Trastuzumab deruxtecanDaiichi SankyoPhase 2
39
Trastuzumab deruxtecanDaiichi SankyoPhase 2
42
Camrelizumab and Apatinib Plus GPSun PharmaceuticalPhase 1/2
28
Recaticimab and Adebrelimab + GP chemotherapySun PharmaceuticalPhase 2
42
Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle)ShionogiPhase 2
35
E6011 + PlaceboEisaiPhase 2
27
LenvatinibEisaiPhase 2
35
gemcitabine + cisplatinEli LillyPhase 2
35
gemcitabine + cisplatinEli LillyPhase 2
35
Ramucirumab + Merestinib + Cisplatin + Gemcitabine + Placebo Oral + Placebo IVEli LillyPhase 2
39
Baricitinib + PlaceboEli LillyPhase 2
27
AbemaciclibEli LillyPhase 2
27
SHR-A1811Jiangsu Hengrui MedicinePhase 2
42
SHR1258Jiangsu Hengrui MedicinePhase 2
27
ApatinibJiangsu Hengrui MedicinePhase 2
31
SHR-1210+GEMOXJiangsu Hengrui MedicinePhase 2
35
Rilvegostomig + Durvalumab + Gemcitabine/CisplatinAstraZenecaPhase 3
47
Durvalumab + Gemcitabine + CisplatinAstraZenecaPre-clinical
33
durvalumabAstraZenecaPhase 3
40
gemcitabine + cisplatin + Placebo + cisplatin + cediranib + gemcitabineAstraZenecaPhase 2/3
38